Table 6.

Profiles of patients eligible for sequential therapy after sorafenib

Author; journal	Patients	Percent of candidates for second-line therapy*	Percent of regorafenib candidate**	Contributing factor to second-line therapy
Ogasawara et al. [13]; Invest New Drugs. 2018; 36 (2):332–9	185 cases CP-A, PS 0–1 Sorafenib 800 mg	70%	45.7%	CP score 5 PS 0
Kuzuya et al. [14]; Hepatol Res. 2019; 49 (9):1054–65	103 cases (excluding discontinuation due to AE) CP-A, PS 0–1 Sorafenib starting dose N/A	57.3%	46.6%	CP score 5 MVI (−)
Uchikawa et al. [15]; Hepatol Res. 2018; 48 (10):814–20	147 cases (excluding discontinuation due to AE) CP-A, PS 0–1 Sorafenib 800 mg	50.3%	30.6%	Alb >3.5 g/dL MVI (−)
Terashima et al. [16]; Hepatol Res. 2018; 48 (12):956–66	125 cases CP-A 72% PS 0 86.4% Sorafenib 800 mg	na	36%	CP score 5, AST <40 IU/L MVI (−)
Yukimoto et al. [17]; JJCO. 2019; 49 (1):42–47	138 cases (excluding discontinuation due to AE) CP-A 85.5% Sorafenib starting dose N/A	na	44.2%	ALBI score < −2.53
Takeda et al. [18]; Cancers. 2019; 11 (9):1256	190 cases CP-A, PS 0–1 Sorafenib starting dose N/A	na	29%	Alb > 3.7 g/dL ALBI score < −2.33 ∆ Alb < −0.2 g/dL at 4 week ∆ ALBI score < 0.255 at 4 week

^*Patients who fulfilled Child-Pugh A and PS ≤ 1 at the PD on sorafenib.

^**Patients who fulfilled Child-Pugh A liver function, PS ≤ 1, and tolerable to sorafenib at the PD on sorafenib. CP score, Child-Pugh score; MVI, Macrovascular invasion; ALBI score, Albumin-Birilbin score; N/A, not available. Bold type denotes important findings.